IconOVir Bio

Executive Summary

IconOVir Bio is a private biotechnology company headquartered in San Diego, California, founded in 2020 with a mission to cure cancer through innovative oncolytic viral therapies. The company operates in the viral technology sector, leveraging engineered viruses that selectively infect and destroy tumor cells while sparing healthy tissue. IconOVir's platform aims to address significant unmet needs in oncology by developing therapies that can be used as monotherapy or in combination with other modalities. Although still in early stages, the company has positioned itself within the competitive oncolytic virus field, which has seen growing interest due to the potential for durable immune responses and tumor regression. The company's current stage and financial details are not publicly disclosed, as it remains private with no reported funding rounds or valuation. Given the preclinical or early clinical nature of its pipeline, key value drivers include advancement of lead programs toward the clinic, securing of financing, and potential partnerships. The oncolytic virus space has experienced both successes and setbacks, but IconOVir's focus on novel viral backbones and delivery strategies could differentiate it. However, the lack of public data and early stage implies high risk. The conviction score reflects cautious optimism based on the therapeutic potential and the company's scientific foundation.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead oncolytic virus candidate70% success
• H2 2026Series A or B financing round80% success
• Q3 2026Preclinical efficacy data presented at major conference90% success